ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO084

Validation of a Six-Point Bedside Risk Score for Prediction of AKI After Transcatheter Aortic Valve Replacement

Session Information

Category: Acute Kidney Injury

  • 101 AKI: Epidemiology, Risk Factors, and Prevention


  • Gargar, Jenn Danielle Mahinay, St. Luke's Medical Center Global City, Metro Manila, Philippines
  • Lim, Annabelle Sy, St. Luke's Medical Center Global City, Metro Manila, Philippines
  • Marcellana, Gwen R., St. Luke's Medical Center Global City, Metro Manila, Philippines
  • Posas, Fabio Enrique Bardales, St. Luke's Medical Center Global City, Metro Manila, Philippines
  • Cruz, Kahlil Carlo A., St. Luke's Medical Center Global City, Metro Manila, Philippines

Post-transcatheter aortic valve replacement (TAVR) acute kidney injury (AKI) is a significant complication linked to increased mortality, dialysis rates and myocardial infarction underscoring the need for a reliable prediction tool. Zivkovic et al. (2018) developed a bedside risk score with six pre-procedural variables (NYHA class, non-femoral access, valve-in-valve procedure, hemoglobin level, creatinine clearance, weight) to predict post-TAVR AKI. Validation of this score improve evidence for wider adoption in patient care.


A retrospective analysis of 205 patients who had TAVR was done. Patient characteristics were compared between AKI and non-AKI groups. Diagnostic accuracy was assessed using the receiver operating characteristics curve.


AKI incidence was 18%. Significant AKI predictors were NYHA class (OR: 2.1170; p=0.001), non-femoral access site (OR: 2.6672; p=0.021), elevated baseline creatinine (OR: 4.1459; p<0.001), decreased hemoglobin levels (OR: 0.6319; p<0.001), eGFR<30 (OR: 0.9634; p<0.001). Age, gender and contrast volume showed no differences. AKI group had higher 10-year follow-up mortality (54.05% vs 31.55%, p=0.010), with 40% of AKI group mortalities occurring in the first year post-TAVR compared to 20% in non-AKI. Post-TAVR dialysis was higher in the AKI group (immediately after: 18.9%, 1 year post-TAVR: 16.2% vs. 0.0% respectively, p<0.001). The bedside risk score demonstrated promising discrimination (AUROC 0.75, accuracy of 69.76%), with a 23.43% increased odds of AKI per score increase.


Zivkovic et al.'s risk score shows promise in predicting post-TAVR AKI and can improve patient care through targeted monitoring and intervention. Guideline development for timely nephrology referral based on the risk score will optimize outcomes for high-risk patients.

Area under the ROC curve of Bedside Risk Score